Handelsbanken Fonder AB Purchases New Position in Twist Bioscience Co. (NASDAQ:TWST)

Handelsbanken Fonder AB purchased a new stake in Twist Bioscience Co. (NASDAQ:TWST) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 18,400 shares of the company’s stock, valued at approximately $855,000.

Several other institutional investors and hedge funds have also recently modified their holdings of TWST. Wilmington Savings Fund Society FSB purchased a new position in shares of Twist Bioscience in the 3rd quarter valued at about $34,000. Van ECK Associates Corp increased its stake in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares in the last quarter. Beaird Harris Wealth Management LLC purchased a new stake in Twist Bioscience during the 3rd quarter worth approximately $95,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after buying an additional 381 shares in the last quarter. Finally, KBC Group NV increased its stake in Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after buying an additional 1,226 shares in the last quarter.

Twist Bioscience Stock Up 0.7 %

Shares of NASDAQ TWST opened at $38.82 on Friday. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The business’s 50 day moving average is $47.64 and its two-hundred day moving average is $45.62. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The firm has a market cap of $2.32 billion, a price-to-earnings ratio of -11.49 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company’s revenue was up 24.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.75) earnings per share. Research analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on TWST. Robert W. Baird boosted their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. JPMorgan Chase & Co. boosted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 4th. Wolfe Research began coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Barclays set a $58.00 price objective on Twist Bioscience and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Finally, Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.40.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 2,940 shares of the company’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $53.13, for a total value of $156,202.20. Following the completion of the transaction, the director now owns 18,173 shares in the company, valued at $965,531.49. This represents a 13.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of the company’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the transaction, the chief financial officer now owns 110,096 shares of the company’s stock, valued at $4,762,752.96. This represents a 5.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,180 shares of company stock valued at $1,821,971 over the last quarter. 3.01% of the stock is owned by insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.